Table 2 Bone marrow cell characteristics measured by fluorescence-activated cell sorting analysis
In vitro pravastatin treated cells | ||
 Bone marrow samples | DMEM (n = 10) | Pravastatin (n = 10) |
 Granulocytes | 31.5 ± 2.6 | 30.8 ± 2.2 |
 Lymphocytes | 37.4 ± 2.6 | 38.6 ± 2.5 |
 Monocytes | 10.3 ± 1.9 | 10.9 ± 1.9 |
 Stromal cells | 7.9 ± 3.6 | 7.5 ± 3.5 |
 Viability | 96.6 ± 3.4 | 97.0 ± 2.5 |
Systemic in vivo pravastatin treatment recipients | ||
 Bone marrow samples | CKD (n = 6) | CKD + pravastatin (n = 5) |
 Granulocytes | 23.6 ± 1.5 | 23.8 ± 1.3 |
 Lymphocytes | 31.76 ± 2.8 | 31.8 ± 2.5 |
 Monocytes | 21.3 ± 0.77 | 16.9 ± 1.3* |
 Stromal cells | 6.04 ± 0.4 | 7.76 ± 0.50* |
 Viability | 96.8 ± 0.4 | 97.7 ± 0.01* |